Skip to main content

Dysphagia Following Cerebrovascular Accident

0
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
Non Invasive vagus nerve stimulationN/A1 trial
Active Trials
NCT06827301Recruiting30Est. Jun 2026
Phagenesis
PhagenesisUK - Manchester
1 program
Pharyngeal Electrical StimulationN/A1 trial
Active Trials
NCT05666141Recruiting84Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
BiocorpNon Invasive vagus nerve stimulation
PhagenesisPharyngeal Electrical Stimulation

Clinical Trials (2)

Total enrollment: 114 patients across 2 trials

NCT06827301BiocorpNon Invasive vagus nerve stimulation

Transcutaneous Auricular Vagus Nerve Stimulation for Treating Post-stroke Dysphagia

Start: Nov 2024Est. completion: Jun 202630 patients
N/ARecruiting
NCT05666141PhagenesisPharyngeal Electrical Stimulation

The Effect of Pharyngeal Electrical Stimulation on Peripheral Biomechanical Aspects of Deglutition

Start: Jun 2022Est. completion: Sep 202584 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 114 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.